950160.KQ
Kolon TissueGene, Inc.
KOE · Healthcare · Biotechnology · US
KRW 16,910.00
−5.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.8B | 5.2B | 5.1B | 3.7B | 9.5B |
| Cost of Revenue | 5.2B | 4.5B | 4.5B | 3.3B | 1.8B |
| Gross Profit | 381.1M | 685.2M | 594.5M | 413.2M | 7.7B |
| Operating Expenses | |||||
| R&D Expense | 6.6B | 1.2B | 5.6B | 5.6B | 7.1B |
| SG&A Expense | 11.7B | 7.6B | 11.8B | 8.9B | 9.9B |
| General & Admin Expense | 4.7B | 6.8B | 11.1B | 8.4B | 9.5B |
| Selling & Marketing Expense | 727.6M | 828.5M | 773.5M | 514.1M | 453.2M |
| Other Expenses | 10.0B | 14.1B | 5.1B | 6.3B | 4.7B |
| Total Operating Expenses | 24.5B | 23.0B | 22.6B | 20.9B | 24.0B |
| Cost and Expenses | 29.0B | 27.5B | 27.1B | 24.2B | 25.8B |
| Operating Income (EBIT) | (24.2B) | (22.3B) | (22.0B) | (20.5B) | (16.3B) |
| Non-Operating | |||||
| Interest Income | 2.8B | 1.8B | 1.0B | 2.2B | 670.5M |
| Interest Expense | 105.5M | 89.5M | 89.8M | 285.8M | 371.2M |
| Net Interest Income | 2.7B | 1.7B | 950.3M | 1.9B | 299.3M |
| Other Non-Op Income/Expense | (155.6B) | (170.1B) | (11.9B) | 3.5B | 6.5B |
| Non-Operating Income (excl Interest) | 213.0B | 170.2B | 11.8B | (3.8B) | (6.9B) |
| EBT (Pre-Tax Income) | (179.8B) | (192.4B) | (33.9B) | (17.0B) | (9.8B) |
| Income Tax Expense | 155.0K | 20.9M | (95.5M) | 253.1M | 1.3B |
| Bottom Line | |||||
| Net Income | (181.5B) | (192.5B) | (33.8B) | (17.2B) | (11.1B) |
| Earnings from Cont. Ops | (181.5B) | (192.5B) | (33.8B) | (17.2B) | (11.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (178.9B) | (192.5B) | (33.8B) | (17.2B) | (11.1B) |
| Per Share | |||||
| Basic EPS | (₩2,192) | (₩2,362) | (₩452) | (₩240) | (₩168) |
| Diluted EPS | (₩2,192) | (₩2,362) | (₩452) | (₩240) | (₩168) |
| Revenue Per Share | ₩56 | ₩63 | ₩68 | ₩52 | ₩143 |
| Shares | |||||
| Basic Shares Outstanding | 84.8M | 81.5M | 74.8M | 71.7M | 66.3M |
| Diluted Shares Outstanding | 84.8M | 81.5M | 74.8M | 71.7M | 66.3M |
| Profitability Metrics | |||||
| EBITDA | (120.4B) | (21.5B) | (33.0B) | (15.3B) | (7.8B) |
| D&A | 904.3M | 777.1M | 808.6M | 1.4B | 1.7B |
| EBIT | (121.3B) | (22.3B) | (33.8B) | (16.7B) | (9.4B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026